Download MendeleyMechanisms of neurotransmitter transport and drug inhibition in human VMAT2.
Pidathala, S., Liao, S., Dai, Y., Li, X., Long, C., Chang, C.L., Zhang, Z., Lee, C.H.(2023) Nature 623: 1086-1092
- PubMed: 37914936
- DOI: https://doi.org/10.1038/s41586-023-06727-9
- Primary Citation of Related Structures:
8T69, 8T6A, 8T6B - PubMed Abstract:
Monoamine neurotransmitters such as dopamine and serotonin control important brain pathways, including movement, sleep, reward and mood 1 . Dysfunction of monoaminergic circuits has been implicated in various neurodegenerative and neuropsychiatric disorders 2 . Vesicular monoamine transporters (VMATs) pack monoamines into vesicles for synaptic release and are essential to neurotransmission 3-5 . VMATs are also therapeutic drug targets for a number of different conditions 6-9 . Despite the importance of these transporters, the mechanisms of substrate transport and drug inhibition of VMATs have remained elusive. Here we report cryo-electron microscopy structures of the human vesicular monoamine transporter VMAT2 in complex with the antichorea drug tetrabenazine, the antihypertensive drug reserpine or the substrate serotonin. Remarkably, the two drugs use completely distinct inhibition mechanisms. Tetrabenazine binds VMAT2 in a lumen-facing conformation, locking the luminal gating lid in an occluded state to arrest the transport cycle. By contrast, reserpine binds in a cytoplasm-facing conformation, expanding the vestibule and blocking substrate access. Structural analyses of VMAT2 also reveal the conformational changes following transporter isomerization that drive substrate transport into the vesicle. These findings provide a structural framework for understanding the physiology and pharmacology of neurotransmitter packaging by synaptic vesicular transporters.
Organizational Affiliation:
Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
